Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

664
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
664
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

619
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
619
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

479
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
479
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

513
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
513
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

633
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
633
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

553
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
553

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification?

Circulation·2023
Same author

Insulin resistance is associated with subclinical myocardial dysfunction and reduced functional capacity in heart failure with preserved ejection fraction.

Journal of cardiology·2023
Same author

Hypoxaemia in patients with heart failure and preserved ejection fraction.

European journal of heart failure·2023
Same author

Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status.

JACC. Heart failure·2023
Same author

Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.

JACC. Heart failure·2023
Same author

Update on Atrial Shunt Therapy for Treatment of Heart Failure.

Structural heart : the journal of the Heart Team·2023
Same journal

WHO Issues Guidelines for Treating Ebola and Marburg Viruses.

JAMA·2026
Same journal

FDA Approves Additional Naloxone Nasal Spray for Opioid Overdose.

JAMA·2026
Same journal

HIV May Hide in More Cells Than Previously Thought-Here's What That Could Mean for a Cure.

JAMA·2026
Same journal

US Dietary Supplement Use Increasing, Especially in Older Adults.

JAMA·2026
Same journal

Heat Stress From Climate Change Surges Globally.

JAMA·2026
Same journal

Strength Training Linked With Lower Cardiovascular Disease Risk in Women.

JAMA·2026
関連記事をすべて見る

関連する実験動画

Updated: Feb 9, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

801

肺動脈高血圧 (肺動脈高血圧) とは,肺動脈高血圧 (肺動脈高血圧) を意味する.

Sanjiv J Shah1

  • 1Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA. sanjiv.shah@northwestern.edu

JAMA
|October 4, 2012
PubMed
まとめ
この要約は機械生成です。

肺高血圧 (PH) は,肺動脈高血圧 (PAH) から区別して,慎重に診断する必要があります. 効果的な管理には,エコーカルディオグラフィーの理解,侵襲的な検査,そしてより良い患者の治療結果を出すために,個別化された治療戦略が含まれます.

さらに関連する動画

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

958
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.7K

関連する実験動画

Last Updated: Feb 9, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

801
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

958
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.7K

科学分野:

  • 心臓病学 心臓病学
  • 肺内科 肺内科 肺内科
  • 医療診断 医療診断

背景:

  • 肺動脈の圧力の上昇によって特徴づけられる肺高血圧 (PH) は一般的であり,死亡率の増加と関連しています.
  • 医師は,呼吸不全や右心不全などの症状を持つ患者を頻繁に診察し,エコーカルディオグラフィでは肺動脈シストリック圧 (PASP) が上昇することが多い.
  • 肺動脈血管拡張剤は通常,肺動脈高血圧 (PAH) 患者で検査されますが,PASP値の上昇だけではPAHが確認されません.

研究 の 目的:

  • より一般的な左心疾患によるPHとPAHを区別することの重要性を強調します.
  • エコカルジオグラフィーや侵入性血液動力学的検査を含む正確な診断方法の必要性を強調する.
  • PHおよび関連する右心不全の適切な治療戦略をガイドする.

主な方法:

  • PHの診断基準とイメージング方法のレビュー.
  • 正確な診断のための侵入性血液動力学パラメータの分析.
  • 異なるタイプのPHの治療戦略の比較.

主要な成果:

  • エコーカルディオグラフィでPASPが上昇することは,PAHの診断には不十分であり,二次的な原因,特に左心疾患がより一般的です.
  • 左心疾患によるPHを血管拡張剤で誤って治療すると,症状が悪化する可能性があります.
  • 左心疾患によるPAHとPHの正確な区別は,効果的な管理に不可欠です.

結論:

  • PHの最適な管理には,エコーカルディオグラフィーと侵襲性血液動力学的検査の徹底的な理解が必要です.
  • 左心疾患に二次的に起因するPAHとPHの区別は,適切な治療法を選択する上で極めて重要です.
  • 証拠に基づいたPHと右心不全の治療戦略の開発は,依然として重要な臨床的課題です.